AstraZeneca
Generated by Meeveem AI
"Global pharmaceutical leader delivering life-changing medicines for cancer, chronic and rare disease"
About AstraZeneca
AstraZeneca is a pharmaceutical company researching, developing and commercialising prescription medicines for cancer, chronic conditions and rare diseases. Formed through the Astra and Zeneca merger in 1999, it has its global headquarters in Cambridge. Its therapy areas include oncology, cardiovascular, renal and metabolic disease, respiratory and immunology, and rare disease.
The group employed 96,100 people at the end of 2025 and has six strategic R&D centres worldwide. In 2025 it invested $14.2 billion in R&D and reported 16 blockbuster medicines, each generating over $1 billion in annual sales. Its pipeline listed 180 projects in October 2026. UK operations combine research in Cambridge with manufacturing, development and other functions in Macclesfield and Speke.
Development across the business
All employees have access to AstraZeneca’s global learning platform. Development programmes support early talent, individual contributors and enterprise leaders, alongside coaching to help colleagues build skills and take on broader responsibilities.
Working across UK sites
The UK network brings together research, manufacturing, supply and business functions. Macclesfield includes pharmaceutical development, global medicines development and IT teams, while the London office connects the UK business with life sciences partners and decision makers.
96100
Team Members
1999
Founded
Pharma
Sector
Hybrid
Work Environment